Among the medicines to be produced at the site will be orforglipron, the company’s oral small-molecule GLP-1 receptor agonist ...

US pharma group says region’s use of ‘one-way insurance system’ to keep down prices is not fair on the industry ...

Eli Lilly invests $3B in a Netherlands plant to produce obesity drug orforglipron, creating new jobs. Read more here.

The new $3 billion manufacturing facility will be sited at the Leiden Bio Science Park in Katwijk, and will be Lilly's first ...

Trump administration pressure on Big Pharma to focus investment on the US has raised concerns in Europe, and specifically the ...

Lilly said the plant will strengthen its global supply chain and expand the capacity for its growing portfolio of oral ...

Eli Lilly and Company (NYSE: LLY) announced today plans to build a new $3 billion manufacturing facility in Katwijk, the ...

Eli Lilly plans to build a $3 billion manufacturing facility in the Netherlands to expand its capacity to produce oral medicines. The pharmaceutical company said Monday that the new facility will be ...

Along with the company’s investment plans in Puerto Rico, Lilly also announced plans to build a $5 billon manufacturing plant ...

US-based medicine company Eli Lilly to invest $3B in a new manufacturing facility in the Netherlands to expand production and create jobs.

The facility is expected to produce oral medications, including Lilly's highly anticipated GLP-1 pill for weight loss, orforglipron.